JP2007521286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007521286A5 JP2007521286A5 JP2006517746A JP2006517746A JP2007521286A5 JP 2007521286 A5 JP2007521286 A5 JP 2007521286A5 JP 2006517746 A JP2006517746 A JP 2006517746A JP 2006517746 A JP2006517746 A JP 2006517746A JP 2007521286 A5 JP2007521286 A5 JP 2007521286A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCN(*)CCN(C)C(*)(*)C[Al]* Chemical compound CCN(*)CCN(C)C(*)(*)C[Al]* 0.000 description 43
- HUSMPKZBAOSVGH-MSOLQXFVSA-N C[C@@H](c(cc1)ccc1Br)N(CC1)[C@H](C)CN1C(CC1)CCN1C(OC(C)(C)C)=O Chemical compound C[C@@H](c(cc1)ccc1Br)N(CC1)[C@H](C)CN1C(CC1)CCN1C(OC(C)(C)C)=O HUSMPKZBAOSVGH-MSOLQXFVSA-N 0.000 description 3
- JHUBNQSPUZXGKI-UHFFFAOYSA-N CC(C)c(cc1)cc2c1OCO2 Chemical compound CC(C)c(cc1)cc2c1OCO2 JHUBNQSPUZXGKI-UHFFFAOYSA-N 0.000 description 2
- LWYFMTMRWRGREZ-UHFFFAOYSA-N CC(C)c1cc(C#N)ccc1 Chemical compound CC(C)c1cc(C#N)ccc1 LWYFMTMRWRGREZ-UHFFFAOYSA-N 0.000 description 2
- RPQZZDWFWOIRAN-UHFFFAOYSA-N CC(C)c1ccc(C(F)(F)F)cc1 Chemical compound CC(C)c1ccc(C(F)(F)F)cc1 RPQZZDWFWOIRAN-UHFFFAOYSA-N 0.000 description 2
- FRGXNJWEDDQLFH-UHFFFAOYSA-N CC(C)c1ccncc1 Chemical compound CC(C)c1ccncc1 FRGXNJWEDDQLFH-UHFFFAOYSA-N 0.000 description 2
- OXHKQGRHPLZUGH-UHFFFAOYSA-N Cc([s]cc1)c1OC Chemical compound Cc([s]cc1)c1OC OXHKQGRHPLZUGH-UHFFFAOYSA-N 0.000 description 2
- IKNQPNLSEBWZKX-UHFFFAOYSA-N Cc(cc1)cc(Cl)c1F Chemical compound Cc(cc1)cc(Cl)c1F IKNQPNLSEBWZKX-UHFFFAOYSA-N 0.000 description 2
- HGDGACBSGVRCSM-UHFFFAOYSA-N Cc1c[s]cc1OC Chemical compound Cc1c[s]cc1OC HGDGACBSGVRCSM-UHFFFAOYSA-N 0.000 description 2
- FBOYMIDCHINJKC-UHFFFAOYSA-N Brc(cc1)cc2c1OCO2 Chemical compound Brc(cc1)cc2c1OCO2 FBOYMIDCHINJKC-UHFFFAOYSA-N 0.000 description 1
- QQNIQRMNEKOPBX-UHFFFAOYSA-N CCCCOc1c(C)[s]cc1 Chemical compound CCCCOc1c(C)[s]cc1 QQNIQRMNEKOPBX-UHFFFAOYSA-N 0.000 description 1
- MXZNLZCPCFVLEH-UHFFFAOYSA-N CCCOc(cc[s]1)c1I Chemical compound CCCOc(cc[s]1)c1I MXZNLZCPCFVLEH-UHFFFAOYSA-N 0.000 description 1
- JSBSMNUHMWSUGB-ITXNJQJZSA-N CCCOc1c(C(CC(CC2)=CCCC2N(CC2)C[C@@H](C)N2[C@@H](C)c2ccc(CCc(cc3)ccc3Cl)cc2)=O)[s]cc1 Chemical compound CCCOc1c(C(CC(CC2)=CCCC2N(CC2)C[C@@H](C)N2[C@@H](C)c2ccc(CCc(cc3)ccc3Cl)cc2)=O)[s]cc1 JSBSMNUHMWSUGB-ITXNJQJZSA-N 0.000 description 1
- KTLZURZEOPZMKJ-RPBOFIJWSA-N CCCOc1c(C(N(CC2)CCC2N(CC2)C[C@@H](C)N2[C@@H](C)c(cc2)ccc2-c2cc(C#N)ccc2)=O)[s]cc1 Chemical compound CCCOc1c(C(N(CC2)CCC2N(CC2)C[C@@H](C)N2[C@@H](C)c(cc2)ccc2-c2cc(C#N)ccc2)=O)[s]cc1 KTLZURZEOPZMKJ-RPBOFIJWSA-N 0.000 description 1
- MNCDTFLKJRBXBT-FTJBHMTQSA-N CCCOc1c(C(N(CC2)CCC2N(CC2)C[C@@H](C)N2[C@@H](C)c2ccc(CCc(cc3)ccc3Cl)cc2)=O)[s]cc1 Chemical compound CCCOc1c(C(N(CC2)CCC2N(CC2)C[C@@H](C)N2[C@@H](C)c2ccc(CCc(cc3)ccc3Cl)cc2)=O)[s]cc1 MNCDTFLKJRBXBT-FTJBHMTQSA-N 0.000 description 1
- ZGIXPQMXXDPWKF-FTJBHMTQSA-N CCCOc1c(C(N(CC2)CCC2N(CC2)C[C@@H](C)N2[C@@H](C)c2ccc(CCc3ccc4OCOc4c3)cc2)=O)[s]cc1 Chemical compound CCCOc1c(C(N(CC2)CCC2N(CC2)C[C@@H](C)N2[C@@H](C)c2ccc(CCc3ccc4OCOc4c3)cc2)=O)[s]cc1 ZGIXPQMXXDPWKF-FTJBHMTQSA-N 0.000 description 1
- QDZYLJJZEADFNS-CQSZACIVSA-N CCCOc1c(C(N(CC2)CCC2N2C[C@@H](C)NCC2)=O)[s]cc1 Chemical compound CCCOc1c(C(N(CC2)CCC2N2C[C@@H](C)NCC2)=O)[s]cc1 QDZYLJJZEADFNS-CQSZACIVSA-N 0.000 description 1
- NOCGTFKCRFTUQN-UHFFFAOYSA-N CCCOc1c(C(O)=O)[s]cc1 Chemical compound CCCOc1c(C(O)=O)[s]cc1 NOCGTFKCRFTUQN-UHFFFAOYSA-N 0.000 description 1
- KFBUGBFIQMNIEO-UHFFFAOYSA-N CCCOc1c(C(OC)=O)[s]cc1 Chemical compound CCCOc1c(C(OC)=O)[s]cc1 KFBUGBFIQMNIEO-UHFFFAOYSA-N 0.000 description 1
- MBYMHSDIEZNZCE-PKTZIBPZSA-N CCCOc1c[s]cc1C(N(CC1)CCC1N(CC1)C[C@@H](C)N1[C@@H](C)c(cc1)ccc1-c1cc(Cl)cc(Cl)c1)=O Chemical compound CCCOc1c[s]cc1C(N(CC1)CCC1N(CC1)C[C@@H](C)N1[C@@H](C)c(cc1)ccc1-c1cc(Cl)cc(Cl)c1)=O MBYMHSDIEZNZCE-PKTZIBPZSA-N 0.000 description 1
- MQDRVHOWRJXGJQ-YADHBBJMSA-N C[C@@H](C(CC1)=CC=C1c1ccncc1)N(CC1)[C@H](C)CN1C(CC1)CCN1C(OC(C)(C)C)=O Chemical compound C[C@@H](C(CC1)=CC=C1c1ccncc1)N(CC1)[C@H](C)CN1C(CC1)CCN1C(OC(C)(C)C)=O MQDRVHOWRJXGJQ-YADHBBJMSA-N 0.000 description 1
- CMYFCWNDXUVHMJ-RPWUZVMVSA-N C[C@@H](c(cc1)ccc1-c1cc(Cl)cc(Cl)c1)N(CC1)[C@H](C)CN1C(CC1)CCN1C(c1c(COCC2CC2)cc[s]1)=O Chemical compound C[C@@H](c(cc1)ccc1-c1cc(Cl)cc(Cl)c1)N(CC1)[C@H](C)CN1C(CC1)CCN1C(c1c(COCC2CC2)cc[s]1)=O CMYFCWNDXUVHMJ-RPWUZVMVSA-N 0.000 description 1
- KIQFKJQHLHAUOR-AGQFNQOXSA-N C[C@@H](c(cc1)ccc1Br)N(CC1)[C@H](C)CN1C(CC1)C[C@@H](C)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](c(cc1)ccc1Br)N(CC1)[C@H](C)CN1C(CC1)C[C@@H](C)N1C(OC(C)(C)C)=O KIQFKJQHLHAUOR-AGQFNQOXSA-N 0.000 description 1
- TZLLCNOMYATBLU-UXHICEINSA-N C[C@@H](c1ccc(C=C)cc1)N(CC1)[C@H](C)CN1C(CC1)CCN1C(OC(C)(C)C)=O Chemical compound C[C@@H](c1ccc(C=C)cc1)N(CC1)[C@H](C)CN1C(CC1)CCN1C(OC(C)(C)C)=O TZLLCNOMYATBLU-UXHICEINSA-N 0.000 description 1
- OJXBIWMWVHZKRM-YADHBBJMSA-N C[C@@H](c1ccc(CCc2ccc3OCOc3c2)cc1)N(CC1)[C@H](C)CN1C1CCN(C)CC1 Chemical compound C[C@@H](c1ccc(CCc2ccc3OCOc3c2)cc1)N(CC1)[C@H](C)CN1C1CCN(C)CC1 OJXBIWMWVHZKRM-YADHBBJMSA-N 0.000 description 1
- HZJKLKAIQVELLV-UHFFFAOYSA-N Ic([s]cc1)c1OCC1CC1 Chemical compound Ic([s]cc1)c1OCC1CC1 HZJKLKAIQVELLV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48361903P | 2003-06-30 | 2003-06-30 | |
| PCT/US2004/020763 WO2005005419A1 (en) | 2003-06-30 | 2004-06-28 | Mch antagonists for the treatment of obesity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007521286A JP2007521286A (ja) | 2007-08-02 |
| JP2007521286A5 true JP2007521286A5 (enExample) | 2008-02-28 |
| JP4605801B2 JP4605801B2 (ja) | 2011-01-05 |
Family
ID=34061963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517746A Expired - Fee Related JP4605801B2 (ja) | 2003-06-30 | 2004-06-28 | 肥満治療用のｍｃｈアンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7345042B2 (enExample) |
| EP (1) | EP1644366A1 (enExample) |
| JP (1) | JP4605801B2 (enExample) |
| CN (1) | CN1812985A (enExample) |
| CA (1) | CA2526725A1 (enExample) |
| MX (1) | MXPA05013596A (enExample) |
| WO (1) | WO2005005419A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005101838A2 (en) * | 2004-04-13 | 2005-10-27 | Incyte Corporation | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| US20080027072A1 (en) * | 2006-04-20 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | Potentiation of MC4 receptor activity |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| CN111093662B (zh) | 2017-06-20 | 2023-10-03 | 安布里亚制药公司 | 用于提高心脏代谢效率的组合物和方法 |
| WO2020081361A1 (en) | 2018-10-17 | 2020-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| TR200103214T2 (tr) | 1999-05-04 | 2002-03-21 | Schering Corporation | CCR5 antagonistleri olarak yararlì piperazin trevleri. |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| MXPA03000174A (es) * | 2000-07-06 | 2003-09-22 | Neurogen Corp | Ligandos de receptor de hormona concentradora de melanina. |
| US6900329B2 (en) * | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| JP2005515961A (ja) * | 2001-05-22 | 2005-06-02 | ニューロジェン コーポレイション | メラニン凝集ホルモン受容体リガンド：置換１−ベンジル−４−アリールピペラジン類似体 |
| HUP0402404A3 (en) * | 2001-11-26 | 2011-05-30 | Schering Corp | Use of new piperidine-based mch antagonists for producing pharmaceutical compositions suitable for the treatment of obesity and cns disorders |
| WO2003059289A2 (en) * | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| WO2004078717A1 (en) * | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
| BRPI0411414A (pt) * | 2003-06-13 | 2006-07-25 | Schering Ag | derivados de quinolil amida como antagonistas de cdr-5 |
-
2004
- 2004-06-28 CN CNA2004800183172A patent/CN1812985A/zh active Pending
- 2004-06-28 MX MXPA05013596A patent/MXPA05013596A/es not_active Application Discontinuation
- 2004-06-28 CA CA002526725A patent/CA2526725A1/en not_active Abandoned
- 2004-06-28 WO PCT/US2004/020763 patent/WO2005005419A1/en not_active Ceased
- 2004-06-28 US US10/878,788 patent/US7345042B2/en not_active Expired - Fee Related
- 2004-06-28 JP JP2006517746A patent/JP4605801B2/ja not_active Expired - Fee Related
- 2004-06-28 EP EP04777221A patent/EP1644366A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4335532B2 (ja) | Ｍｃｈアンタゴニストおよび肥満治療でのそれらの使用 | |
| JP4643141B2 (ja) | 肥満治療用のｍｃｈアンタゴニスト | |
| JP2005510563A (ja) | 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト | |
| JP2010047618A (ja) | 肥満症および関連障害の処置のための、選択的メラニン凝集ホルモンレセプターアンタゴニストとしての２置換ベンズイミダゾール誘導体。 | |
| JP4330996B2 (ja) | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 | |
| JP2011006469A (ja) | 肥満および関連障害の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしての二環式化合物 | |
| JP4522853B2 (ja) | 肥満の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしてのスピロ置換ピペリジン | |
| JP4605801B2 (ja) | 肥満治療用のｍｃｈアンタゴニスト | |
| JP2007521286A5 (enExample) | ||
| JP4570165B2 (ja) | 肥満および関連障害の処置のための選択的ｍｃｈレセプターアンタゴニストとしてのビアリールテトラヒドロイソキノリンピペリジン | |
| JP2006520399A5 (enExample) | ||
| JP4672662B2 (ja) | 肥満およびそれに関連した障害を治療するための選択的メラニン濃縮ホルモンレセプタアンタゴニストとしての２−置換ベンゾイミダゾールピペリジン | |
| JP2007504146A5 (enExample) | ||
| EP1667679B1 (en) | Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | |
| US7361769B2 (en) | Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |